Patent · US Active

Antibodies targeting M-CSF

US10081675B2 · kind B2 · utility

0Cited by

4References

10Claims

0Family size

Assignee

MORPHOSYS AG · DE

Inventors

Francis Dodeller · Gilching, DE
Robert Rauchenberger · Martinsried, DE

Key dates

Filing date	Oct 27, 2017
Grant date	Sep 25, 2018
Priority date	—
Expiry date	Oct 27, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

This disclosure generally relates to antibodies or antibody fragments which specifically bind to M-CSF. In particular antibodies and antibody fragments are disclosed which bind to M-CSF and which inhibit binding of M-CSF to the M-CSF receptor with an IC50 of 10 pM or less. The invention also relates to nucleic acids, vectors and host cells capable of expressing the antibodies or fragments thereof of the invention, pharmaceutical compositions comprising the antibodies or fragments thereof and uses of said antibodies or fragments thereof and compositions for treatment of specific diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.